ID   MCF-7 Tam1
AC   CVCL_A4AQ
SY   MCF7/TAM1; MCF7:TAM1
DR   ATCC; CRL-3435
DR   cancercelllines; CVCL_A4AQ
DR   ChEMBL-Cells; CHEMBL4630711
DR   ChEMBL-Targets; CHEMBL4630717
DR   PubChem_Cell_line; CVCL_A4AQ
DR   Wikidata; Q105510077
RX   PubMed=27378269;
CC   Population: Caucasian.
CC   Doubling time: ~1-2 weeks (ATCC=CRL-3435).
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 6
//
RX   PubMed=27378269; DOI=10.1186/s12885-016-2452-5; PMCID=PMC4932681;
RA   Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P.,
RA   Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.;
RT   "Systematic drug screening reveals specific vulnerabilities and
RT   co-resistance patterns in endocrine-resistant breast cancer.";
RL   BMC Cancer 16:378.1-378.17(2016).
//